First, a pricing scandal for Catalyst’s Firdapse. Next, off-label competition?
For decades, Jacobus Pharmaceuticals gave away the unapproved drug amifampridine to patients with a rare neuromuscular disorder called LEMS. Then, Catalyst Pharma licensed certain rights to the drug, scored an FDA nod, and priced the med at $ 375,000 a year. An outcry ensued. But now, the FDA may have given patients a workaround. Jacobus… Read More »